本报道最初发表于Endpoints News。请点击这里查看原文
Attempts by the White House to curry industry support for legislation that would codify last year’s voluntary drug pricing deals are being ignored by some drugmakers who believe there’s little to negotiate.
白宫试图为一项将去年自愿药价协议写入成文法的立法拉拢业界支持，但一些药企不予理会，认为几无可谈。
您已阅读5%（286字），剩余95%（5051字）包含更多重要信息，订阅以继续探索完整内容，并享受更多专属服务。